Join
Live feed
·
PRReleasevia Quantisnow
Aktis Oncology Inc. logo

Aktis Oncology Initiates Phase 1b Clinical Trial for AKY-2519, a B7-H3 Miniprotein Radioconjugate, in Metastatic Castration-Resistant Prostate Cancer (mCRPC)

ByQuantisnow·Wall Street's wire, on your screen.
AKTS· Aktis Oncology Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track AKTS (Aktis Oncology Inc.) and more on Quantisnow.